FELIX FABER

Mindpeak sits in a space that has been waiting for change for a long time. Pathology has always depended on sharp eyes, steady hands and years of experience. But labs today face a different kind of pressure. Caseloads keep rising. Cancer diagnostics keep getting more complex. And the number of trained pathologists is not growing at the same pace. Anyone who has spent time in this field knows how real that gap feels.

This is where Mindpeak, based in Hamburg, brings something genuinely useful to the table. Not flashy. Not futuristic for the sake of it. Just practical AI tools that help pathologists do what they already do, only faster and with more clarity. And maybe with a little less fatigue at the end of the day.

The company started in 2018, and its focus has stayed consistent since then: build AI that learns the way pathologists think. That means single-cell analysis, reliable detection of signals in immunohistochemistry slides, and a workflow that fits into the lab instead of disrupting it. I’ve spoken to enough pathologists to know that this last part matters more than anything. If a tool adds friction, it never sticks.

Mindpeak’s technology sits in that sweet spot between rigorous science and real-world usability. Their team has built deep-learning models that handle messy data, lab-to-lab variations and the quirks of staining that always show up in practice. They treat explainability as a requirement, not an add-on. When the software highlights a cell or classifies a region, the pathologist can see why. It feels familiar, almost like watching another expert annotate a slide alongside you.

What makes their approach stand out is the amount of detail they capture. Their algorithms assess tissue on a cell-by-cell level, separate tumor regions from surrounding areas and quantify biomarkers in a way that keeps the interpretation consistent. And consistency is a quiet but powerful word in pathology. One pathologist’s “borderline” is another’s “positive.” Tools like Mindpeak help smooth those edges so clinical decisions feel more grounded.

The product portfolio covers the markers that labs deal with every day. HER2. Ki-67. ER and PR. PD-L1. The usual lineup for breast cancer and several others. They also work across H&E, multiplex immunofluorescence and research-grade datasets. Labs can plug the tools into existing scanners and image management systems, which removes one of the biggest barriers to adoption. Nobody wants to overhaul a setup that already works.

And then there’s the impact on workflow. I remember a pathologist once saying that what drains their time is not the complex cases. It’s the repetitive counting. The endless quantification. Tasks that feel mechanical but still carry clinical weight. Mindpeak’s tools speed up those steps without changing how the pathologist makes the final call. Ten minutes of manual review drops to a few seconds of automated analysis. The pathologist still leads the diagnosis. The AI just handles the heavy lifting.

There’s also the research side, which often gets overlooked. Pharmaceutical companies and clinical research groups use Mindpeak’s platform to analyze biomarkers, segment tissue and identify patterns across large datasets. Precision medicine depends on reliable quantification, and AI helps scale that work. Without it, many trials would move slower than the science itself.

Mindpeak’s growth tells its own story. Investors backed the company with significant Series A funding, and its tools now support tens of thousands of patient cases worldwide. Several well-known industry players have brought them into their platforms, which says something about how the technology performs outside a controlled environment. It’s easy for an AI model to shine in a lab demo. It’s much harder for it to perform reliably across different labs, scanners and staining techniques. Mindpeak has crossed that line.

All of this is pushing pathology toward a more digital, more predictable future. Not a replacement for expertise. Something more like an amplifier. When labs gain more capacity, reports turn around faster. When quantification becomes consistent, oncologists feel more confident in their treatment plans. When pathologists have more time for complex cases, the entire system benefits. And sometimes that benefit looks simple. A quicker answer for a patient who has been waiting all week.

Mindpeak positions itself as a pathology solution provider, but the phrase doesn’t fully capture what they’re building. They aren’t just selling tools. They’re shaping how digital pathology actually becomes part of the everyday workflow. Not five years from now. Today. In real labs with real constraints.

If I had to summarize the company in a single thought, it would be this: Mindpeak understands pathology from the inside. The pace, the pressure, the bottlenecks, the moments where a second opinion helps. Their AI doesn’t push the field in a direction it wasn’t already going. It just clears the path a little faster.

And in a specialty where time and clarity matter so much, that feels like the kind of progress people will remember.